Gemcitabine and Carboplatin Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Feasibility Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Although platinum based chemotherapy is known to improve the survival duration for the patients with non-small cell lung cancer, the role of platinum for elderly patient is not yet clear. We administered gemcitabine and carboplatin combination therapy to elderly patients with NSCLC. The aim of this study was to evaluate the efficacy and toxicities of this regimen for elderly patients. Materials and Methods: The eligibility criteria were as follows: pathologically confirmed NSCLC, an age ≥ 65 years, advanced disease with stage IIIB or IV and the patients were chemotherapy-naive. The treatment regimen was as follows; gemcitabine 1,000 mg/m² was administered on days 1 and 8 and carboplatin AUC=5 was administered on day 1. This regimen was repeated every 3 weeks. The efficacy was evaluated in terms of the response rate, the time to progression and the overall survival duration. Results: From Dec 2001 to Feb 2005, a total of 20 patients were entered into this study. The median patient age was 68 years (range: 65∼75). 19 patients were evaluable for their treatment response. A partial response was obtained in 8 patients (response rate: 42.1%, 95% CI: 19.4∼64.8%). The median time to progression and the survival duration were 136 days and 453 days, respectively. Among a total of 65 cycles of treatment, grade 3 or 4 leukopenia and thrombocytopenia were observed in 7.7% and 13.9% of the cycles, respectively. Grade 3 or 4 vomiting was observed in 7.7% of the cycles. Grade 3 skin rash developed in 1.5% of the cycles. 1 patient died of septic shock after chemotherapy. Conclusions: Gemcitabine and carboplatin combination chemotherapy was relatively safe and effective for treating elderly patients with NSCLC.
Abstract
Purpose: Although platinum based chemotherapy is known to improve the survival duration for the patients with non-small cell lung cancer, the role of platinum for elderly patient is not yet clear. We administered gemcitabine and carboplatin combination therapy to elderly patients with NSCLC. The aim of this study was to evaluate the efficacy and toxicities of this regimen for elderly patients. Materials and Methods: The eligibility criteria were as follows: pathologically confirmed NSCLC, an age ≥ 65 years, advanced disease with stage IIIB or IV and the patients were chemotherapy-naive. The treatment regimen was as follows; gemcitabine 1,000 mg/m² was administered on days 1 and 8 and carboplatin AUC=5 was administered on day 1. This regimen was repeated every 3 weeks. The efficacy was evaluated in terms of the response rate, the time to progression and the overall survival duration. Results: From Dec 2001 to Feb 2005, a total of 20 patients were entered into this study. The median patient age was 68 years (range: 65∼75). 19 patients were evaluable for their treatment response. A partial response was obtained in 8 patients (response rate: 42.1%, 95% CI: 19.4∼64.8%). The median time to progression and the survival duration were 136 days and 453 days, respectively. Among a total of 65 cycles of treatment, grade 3 or 4 leukopenia and thrombocytopenia were observed in 7.7% and 13.9% of the cycles, respectively. Grade 3 or 4 vomiting was observed in 7.7% of the cycles. Grade 3 skin rash developed in 1.5% of the cycles. 1 patient died of septic shock after chemotherapy. Conclusions: Gemcitabine and carboplatin combination chemotherapy was relatively safe and effective for treating elderly patients with NSCLC.
참고문헌 (21)
- Parkin DM, "Global cancer statistics in the year 2000", Lancet Oncol, 2, pp.533~43 (2001)
- 김소연, "진행성 비소세포폐암 환자에서 제1차 요법으로서 매주요법 Docetaxel", Platinum 복합항암화학요법의 효과, 2007, pp.72(6), 625~631[DOI]
- Gridelli C., "Lung cancer in the elderly", Eur J Cancer, 33, pp.2313~4 (1997)
- Non-small Cell Lung Cancer Collaborative Group, "Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials", BMJ, 311, pp.899~909 (1995)
- Hutchins LF, "Underrepresentation of patients 65 years of age or older in cancer-treatment trials", N Engl J Med, 341, pp.2061~7 (1999)
- The Elderly Lung Cancer Vinorelbine Italian Study Group, "Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer", J Natl Cancer Inst, 91, pp.66~72 (1999)
- Earle CC, "Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis", J Clin Oncol, 19, pp.1064~70 (2001)
- Ricci S., "Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study", Lung Cancer, 27, pp.75~80 (2000)
- Bianco V., "Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study", Anticancer Res, 22, pp.3053~6 (2002)
- Klastersky J., "A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced nonsmall- cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861", J Clin Oncol, 8, pp.1556~62 (1990)
- Sederholm C., "Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group", J Clin Oncol, 23, pp.8380~8 (2005)
- Masters GA, "A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer", J Thorac Oncol, 1, pp.19~24 (2006)
- Schiller JH, "Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer", N Engl J Med, 346, pp.92~8 (2002)
- Iaffaioli RV, "Phase I-II study of gemcitabine and carboplatin in Stage IIIB-IV non-small cell lung cancer", J Clin Oncol, 17, pp.921~6 (1999)
- Rinaldi M., "A three-week schedule of gemcitabinecisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial", Ann Oncol, 11, pp.1295~300 (2000)
- Cardenal F., "Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer", J Clin Oncol, 17, pp.12~8 (1999)
- Mazzanti P., "Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer", Lung Cancer, 41, pp.81~9 (2003)
- Go RS, "Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin", J Clin Oncol, 17, pp.409~22 (1999)
- Hainsworth JD, "Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma", Cancer, 89, pp.328~33 (2000)
- Gridelli C., "Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel", J Clin Oncol, 23, pp.3125~37 (2005)
- Gridelli C., "Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel", J Clin Oncol, 23, pp.3125~37 (2005)